Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder

Journal of Clinical Psychopharmacology

Volumn 26, Issue 1, 2006, Pages 79-83

  Koran, Lorrin M ^a,d   Aboujaoude, Elias ^a   Ward, Herbert ^b   Shapira, Nathan A ^b   Sallee, Floyd R ^c   Gamel, Nona ^a   Elliott, Michael ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; NORCLOMIPRAMINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ZIPRASIDONE;

ADULT; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PULSE THERAPY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEMOGLOBINURIA; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; MALE; MULTICENTER STUDY; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEXUAL DYSFUNCTION; SIDE EFFECT; TACHYCARDIA; THERAPY RESISTANCE; TREATMENT OUTCOME; TREMOR; VOLUNTEER; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CLOMIPRAMINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT FAILURE;

EID: 31544470340     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000195112.24769.b3     Document Type: Article

References (20)

1. Karao M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45:1094-1099.
2. Warneke LB. The use of intravenous chlorimipramine in the treatment of obsessive compulsive disorder. Can J Psychiatry. 1984;29:135-141.
3. Fallon BA, Campeas R, Schneier FR, et al. Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder. J Neuropsychiatry. 1992;4:70-75.
4. Koran LM, Faravelli C, Pallanti S. Intravenous clomipramine for obsessive-compulsive disorder. J Clin Psychopharmacol. 1994;14:216-218.
5. Koran LM, Pallanti S, Paiva RS, et al. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive compulsive disorder. Eur Neuropsychopharmacol. 1998;8:121-126.
6. Koran LM, Sallee FR, Pallanti S. Intravenous pulse loading of clomipramine produces rapid benefit in obsessive-compulsive disorder. Am J Psychiatry. 1997;154:396-401.
7. Mundo E, Pirola R, Bellodi L, et al. Are gender differences in antiobsessional response related to different clomipramine metabolism? [letter]. J Clin Psychopharmacol. 2002;22:341-342.
8. Mavissakalian M, Jones B, Olson S, et al. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive compulsive disorder. Psychopharmacol Bull. 1990;26:119-122.
9. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, version 2.0). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1996.
10. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
11. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. DHEW publication no. (ABM) 76-338. Rockville, Md; 1976.
12. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effects rating scale: scale for the registration of unwanted effects of psychotropics. Manual. [English version] October 1986. Acta Psychiatr Scand. 1987;76(suppl 334):1-100.
13. Sallee FR, Pollock BG, Perel JM, et al. Intravenous pulse loading of clomipramine in adolescents with depression. Psychopharmacol Bull. 1989;25:114-118.
14. Denys D, Burger H, van Megen H, et al. A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2003;18:315-322.
15. Tollefson GD, Rampey AH Jr, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51:559-567.
16. Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001;16:75-86.
17. Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol. 2002;12:181-186.
18. Koran LM, Cain JW, Dominguez RA, et al. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Am J Psychiatry. 1996;153:1450-1454.
19. Greist J, Chouinard G, Duboff E, et al. Double-blind parallel comparison of three doses of sertraline and placebo in outpatients with obsessive compulsive disorder. Arch Gen Psychiatry. 1995;52:289-295.
20. Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. J Clin Psychiatry. 1999;60:584-590.